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Heavy smoking can induce airway inﬂammation and emphysema. Macrolides can modulate inﬂammation and eﬀector T-cell res-
ponse in the lungs. However, there is no information on whether erythromycin can modulate regulatory T-cell (Treg) response.
This study is aimed at examining the impact of erythromycin on Treg response in the lungs in a rat model of smoking-induced
emphysema. Male Wistar rats were exposed to normal air or cigarette smoking daily for 12 weeks and treated by gavage with
100mg/kg of erythromycin or saline daily beginning at the forth week for nine weeks. The lung inﬂammation and the numbers of
inﬂammatory inﬁltrates in bronchoalveolar lavage ﬂuid (BALF) were characterized. The frequency, the number of Tregs, and
the levels of Foxp3 expression in the lungs and IL-8, IL-35, and TNF-α in BALF were determined by ﬂow cytometry, RT-PCR and
ELISA,respectively.Treatmentwitherythromycinreducedsmoking-inducedinﬂammatoryinﬁltrates,thelevelsofIL-8andTNF-α
in the BALF and lung damages but increased the numbers of CD4+Foxp3+ Tregs and the levels of Foxp3 transcription in the lungs,
accompaniedbyincreasedlevelsofIL-35intheBALFofrats.OurnoveldataindicatedthaterythromycinenhancedTregresponses,
associated with the inhibition of smoking-induced inﬂammation in the lungs of rats.
1.Introduction
Chronicobstructivepulmonarydisease(COPD)isoneofthe
most prevalent illnesses worldwide and is estimated as the
third leading cause of mortality in 2020 [1].COPD is charac-
terised by airﬂow limitation that is poorly reversible. The
pathogenesis of COPD is usually progressive and associated
with an abnormal inﬂammatory response in the lungs, par-
ticularly in response to noxious particles or gases, such as
cigarette smoke [2]. Recently, COPD-associated inﬂamma-
tion is thought to be an autoimmune response induced
by smoking or pathogenic microbials that activate lympho-
cytes and antigen-presenting cells [3]. Previous studies have
shown that Th1 cells are predominantly associated with the
development of emphysematous lungs, leading to the prog-
ressionofCOPDalthoughthemechanismsbywhichtobacco
smoke is associated with Th1 immunity remain unclear [4–
7].
CD4+CD25+Foxp3+ regulatory T cells (Tregs) are crucial
regulators of the maintenance of peripheral immunologic
tolerance, and Tregs can suppress eﬀectors Th1, Th2, and
Th17 responses, inﬂammation, and autoimmune responses
[8, 9]. Tregs can secrete IL-35, which inhibits inﬂammatory
responses[10].AdeﬁciencyinTregregulationhasbeenasso-
ciated with the development of many Th1-mediated chronic
inﬂammation and autoimmune disorders, including type 1
diabetes, multiple sclerosis, atherosclerosis, and rheumatoid
arthritis [11–14]. Interestingly, decreased numbers of Tregs
were detected in the lungs of subjects with emphysema
[15], suggesting that Tregs participate in the regulation of
emphysema-related inﬂammation in the lungs. However,
little is known on what therapeutic strategies could increase
the number of Tregs and IL-35 responses in the lungs of
subjects with emphysema-related inﬂammation. Currently,
anti-inﬂammatory steroids have been often used for the
treatment of COPD patients with acute exacerbation, but the
therapeutic eﬃcacy of steroids is limited [16, 17]. Therefore,
discovery of new therapeutic reagents will be of great sig-
niﬁcance in the management of patients with COPD.2 Mediators of Inﬂammation
Erythromycin is a 14-membered ring macrolide antibi-
otic and has been prescribed for the treatment of various
respiratory infections. Erythromycin can inhibit mitogen-
stimulated human T-cell proliferation and cytokine produc-
tion, which are associated with inhibition of the MAPK and
NF-κBa c t i v a t i o n[ 18, 19]. Furthermore, erythromycin can
ameliorate chronic inﬂammation in various animal models
[20, 21]. In addition, long-term treatment with low doses
of a 14-membered ring macrolide is beneﬁcial for patients
with airway inﬂammatory diseases, such as diﬀuse panbron-
chiolitis (DPB) [22], cystic ﬁbrosis [23, 24], bronchiectasis
[25], and bronchial asthma [26, 27]. Our previous study has
reportedthattreatmentwitherythromycinreducesthenum-
ber of smoking-induced airway inﬂammatory inﬁltrates and
airway remodelling in the lungs of rodents [28]. However,
little is known on whether treatment with erythromycin
could modulate Treg and IL-35 responses in the lungs.
In this study, we evaluated the impact of treatment with
erythromycin for nine weeks on cigarette smoking-induced
inﬂammation in a rat model of emphysema. Our ﬁndings
indicatedthattreatmentwitherythromycinnotonlyreduced
smoking-induced airway inﬂammation and emphysema but
also increased Treg inﬁltrates and IL-35 production in the
lungs of rats.
2.MaterialsandMethods
2.1. Animals and Treatments. Male Wistar rats at 12 weeks of
age were obtained from the Animal Research Center of
Guangxi Medical University. The animals were housed indi-
vidually in standard laboratory cages with free access to
standard food and tap water ad libitum.T h ee x p e r i m e n t a l
protocols were established, according to the guidelines of
NIHAnimalResearchCareandwereapprovedbytheAnimal
Research Care Committee of Guangxi Medical University.
Individual rats (n = 40) were exposed either to room
air (control) or to cigarette smoke, as described previously
[28] .B r i e ﬂ y ,g r o u p so fr a t s( n = 20 per group) were exposed
to tobacco smoke with 20 cigarettes (Nanning Jiatianxia
unﬁltered cigarettes: 12mg of tar and 0.9mg of nicotine) in a
closed0.54m3 spacefor2hoursdailyforsixconsecutivedays
per week for 12 consecutive weeks. As a result, an optimal
ratio of smoking to air at 1:6 was obtained and the levels of
oxygen exposed by the rats were kept at a 21 ± 1%, which is
similar to atmospheric oxygen concentrations. The rats tol-
erated the cigarette smoke without evidence of toxicity (the
levels of serum carboxyhemoglobin in rats were at ∼10%,
and no weight loss in the rats was observed). The levels
of serum carboxyhemoglobin in the smoking rats (n = 20)
were 8.3 ±1.4%, as compared with 1.0 ±0.2% in the control
rats (n = 20), which were similar to the concentrations of
blood carboxyhemoglobin of human smokers [29].
Three weeks after exposure to cigarette smoke, the rats
were randomized and treated by gavage with 100mg/kg/d of
erythromycin (Meichuang Pharmaceuticals, Dailian, China)
in saline (1mL) or saline alone daily for nine weeks, respec-
tively. We used this dose based on our previous ﬁndings
to show that treatment with 100mg/kg/d of erythromycin
inhibits smoke-related lung inﬂammation without obvious
adverse eﬀect [28]. The rats that exposed to regular air were
randomized and treated with erythromycin or saline in the
same manner. Accordingly, there were four groups of rats
(n = 10 per group). The normal group of rats were exposed
to regular air and treated with saline (group N); the smoking
group of rats were exposed to smoking air for 12 weeks and
treated with saline (group S); the erythromycin group of
rats were exposed to smoking air for 12 weeks and treated
with erythromycin (group E); the control group of rats were
exposed to regular air and treated with erythromycin (group
C).
One day after the last smoking, animals were injected
intraperitoneally with 20mg/kg pentobarbital and subjected
to a thoracotomy. Their left lungs were lavaged through an
intratracheal cannula three times with 2mL of cold saline,
and the bronchoalveolar lavage ﬂuid (BALF) samples were
collected. The left lungs were used for the preparation of
single cell suspension. The lower lobes of their right lungs
were ﬁxed in 10% formalin for pathological examination.
2.2. Histology. The ﬁxed lower lobes of the right lungs were
embedded in paraﬃn, and the midsagittal sections of the
lungs were stained with hematoxylin and eosin (H&E), fol-
lowed by examining under a light microscope. Three non-
consecutive lung sections from each animal and three non-
overlapping random ﬁelds from each section were examined
for the quantiﬁcation of lung damages. Alveolar airspace
enlargement was assessed by the mean linear intercept (MLI)
by two independent individuals in a blinded manner, as des-
cribed previously [30]. Brieﬂy, multiple digital images of
histological sections were systematically captured at 100 ×
magniﬁcation. Images were overlaid with a 10 × 10 grid
(1mm2), and the MLI was established from every second
image (i.e., in a checkerboard fashion, averaging six images
for each rat). The distribution of the MLI values of all the
digital photographs was assessed using frequency distribu-
tion analysis and characterized using a Gaussian model.
2.3.CharacterizationofInﬂammatoryCellsinBALF. Thecol-
lected BALF samples from the left lung tissues were cen-
trifuged, and their supernatants were stored at −80◦Cf o r
ELISA analysis. The pelleted cells were resuspended in PBS
and a portion of the cells (1 × 105 cells) was subjected to
cytospin centrifugation on glass slides and ﬁxed with me-
thanol, followed by staining with May-Gr¨ unwald-Giemsa
solution, and a diﬀerential cell count was performed under a
lightmicroscope,accordingtomorphologicalcharacteristics.
2.4. Measurement of IL-8, IL-35, and TNF-α in BALF. The
concentrations of IL-8, IL-35, and TNF-α in BALF were
measured with a multiplex-enzyme-linked immunosorbent
assay (ELISA) system, according to the manufacturers’ ins-
tructions (Lincoplex Systems, St Charles, MO, USA).
2.5. Lung Cell Preparation. A single-cell suspension of whole
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mechanical fragmentation, enzymatic digestion, and centri-
fugation, as described in previous studies [5, 15]. The pre-
pared lung cells were used for ﬂow cytometry analyses.
Brieﬂy, lungs were ﬂushed via the right ventricle with 10mL
of warm (37◦C) HBSS (calcium and magnesium free) con-
taining 5% fetal bovine serum (FBS, Sigma, Beijing, China),
100U/mL of penicillin, and 100μg/mL of streptomycin
(Gibco BRL). The lungs were then cut into small pieces
(∼2mm in diameter) and digested with 150U/mL of colla-
genase (Worthington Biochemical, Freehold, NJ, USA) in
HBSS with being shaken at 37◦C for 1h. Using a plunger
from a 5-mL syringe, the lung pieces were triturated
through a mess of 100μM into HBSS, and the resulting cell
suspension was ﬁltered through nylon mesh. The cells were
washed twice, and mononuclear cells were isolated using
density centrifugation in 30% percoll (Pharmacia, Uppsala,
Sweden). The total numbers of cells were counted. The col-
lected leukocytes (1×106 cells) were used for ﬂow cytometry
analysis and the remaining cells were used for the extraction
of total RNA for RT-PCR analysis.
2.6. Flow Cytometry. The collected cells (1 × 106) from indi-
vidual rats were stained with PE-Cy5-conjugated anti-CD4
(clone: OX-35) or its isotype control (BD Pharmingen, San
Diego,CA,USA)at4◦Cfor45minutes,ﬁxed,permeabilized,
and stained with PE-conjugated anti-Foxp3 (clone: FJK16s)
or its isotype control (eBioscience, Wembley, UK) at 4◦Cf o r
another 40 minutes. The frequency and the number of Tregs
were determined by ﬂow cytometry on a FACSCalibur (BD
PharMingen) and analysed by FCS Express software.
2.7. RNA Isolation and RT-PCR. Total RNA was extracted
from the lung cells of individual rats with TRIzol reagent,
according to the manufacturers’ instructions (Invitrogen,
Carlsbad, CA, USA). The quality and quantity of total RNA
were analysed by a spectrophotometer. The RNA samples
were reversely transcribed into cDNA using a reverse trans-
cription kit (Finn-zymes, Espoo, Finland) and oligo (dT)
primers. The relative levels of Foxp3 mRNA transcripts to
control β-actin in individual samples were characterized by
quantitative RT-PCR using SYBR Green on a LightCycler
(iCycler IQ, BioRad, USA) and the speciﬁc primers. The
sequences of primers were forward 5 -GGAGATTAC-
TGCCCTGGCTCCTA-3 ,a n dr e v e r s e5  -GACTCATCG-
TACTCCTGCTTGCTG-3  for β-actin and forward 5 -TGA-
GCTGGCTGCAATTCTGG-3  and reverse 5 -ATCTAGCTG-
CTCTGCATGAGGTGA-3  for Foxp3. The PCR ampliﬁca-
tions were performed in triplicate at 95◦Cf o r3 0 s e ca n d
subjected to 40 cycles of 95◦Cf o r5s e ca n d6 0 ◦Cf o r3 0s e c .
The values of Foxp3 mRNA transcripts in each sample were
normalized to that of β-actin and the relative levels of Foxp3
mRNA transcripts were calculated.
2.8. Statistical Analysis. Data are expressed as means ± SD.
Diﬀerences among groups were analysed using the analysis
of variance (ANOVA) and post hoc Student’s t-test, the
Kruskal-Wallistest,andtheMann-WhitneyU-testwhereap-
plicable using statistical package SPSS 11.0 (SPSS, Chicago,
IL, USA). The association between two variants was analyzed
using Spearman’s rank method. A P value of <0.05 was con-
sidered statistically signiﬁcant.
3. Results
3.1. Treatment with Erythromycin Reduces the Smoking-In-
duced Lung Damages in Rats. Following smoking for 12
weeks and treatment with erythromycin for 9 weeks, the
lung tissue sections of the diﬀerent groups of rats were
stained with H&E and subjected to quantitative analysis of
the lung airspace (Figure 1). We observed the enlargement
of air spaces and many inﬂammatory inﬁltrates in the lungs
ofthesmokingrats.Quantitativeanalysisindicatedthatthere
was no signiﬁcant diﬀerence in the MLI values between the
N and C groups of rats. In contrast, the MLI values in the S
and E group of rats were signiﬁcantly greater than that in
t h eNa n dCg r o u p so fr a t s( P<0.05), demonstrating that
long-term heavy smoking-induced lung emphysema in rats.
Interestingly, the MLI values in the E groups of rats were
signiﬁcantly less than that in the S group of rats although
they remained greater than that in controls. In addition,
treatment with erythromycin mitigated smoke-induced his-
tologicaldamageinthelungsofrats,consistentwithourpre-
vious observation [28]. These data indicated that treatment
with erythromycin signiﬁcantly diminished smoking-related
emphysema in the lungs of rats.
3.2. Treatment with Erythromycin Modulates the Smoking-
Induced Inﬂammatory Inﬁltrates in BALF. To quantify the
airway inﬂammation response, we evaluated the numbers
of inﬂammatory inﬁltrates in BALF and found signiﬁcantly
increased numbers of total inﬁltrates, particularly macro-
phages, lymphocytes, and neutrophils in the BALF from the
smoking rats, as compared with that in the N and C groups
of rats (P<0.05, Figure 2). In contrast, the total numbers
of inﬂammatory inﬁltrates, macrophages, lymphocytes, and
neutrophils in the BALF from the erythromycin-treated
smoking rats were reduced signiﬁcantly, as compared with
those in the smoking rats without erythromycin treatment.
In addition, treatment with erythromycin did not cause
obvious adverse eﬀect in rats, consistent with our previous
ﬁndings [28]. These data demonstrated that treatment
with erythromycin signiﬁcantly mitigated smoking-induced
inﬂammatory cell inﬁltration in the lungs of rats.
3.3. Treatment with Erythromycin Alters the Levels of TNF-α
and IL-8 in BALF. Analysis of the concentrations of TNF-
α and IL-8 in the BALF indicated that signiﬁcantly higher
levels of TNF-α a n dI L - 8w e r ed e t e c t e di nB L A Ff r o mt h e
smoking rats, as compared with that in the N and C groups
of rats (Figure 3). Furthermore, the levels of TNF-α and IL-
8 in BALF from the smoking rats that had been treated
with erythromycin were signiﬁcantly lower than that in the
smoking rats without erythromycin treatment. Apparently,
treatmentwitherythromycininhibitedthesmoking-induced



























Figure 1: Treatment with erythromycin protects against the smoking-induced emphysema in rats. The lung tissue sections from diﬀerent
groupsofratsweresubjected toH&E staining,andthealveolar airspaceenlargement was assessedusingMLIbytwoindependent individuals
in a blinded manner. Data are representative images or expressed as mean value ± SD of each group of rats (n = 10) from ﬁve separate
experiments. (a) Morphological changes in the lungs of rats (magniﬁcation × 100). (b) Quantitative analysis of alveolar airspace. Group N:
rats exposed to regular air without any special treatment; Group C: rats exposed to regular air and were treated with erythromycin; Group S:
rats exposed to smoking air and were treated with saline; Group E: rats exposed to smoking air and were treated with erythromycin daily for
nine weeks beginning at the forth weeks smoking. ∗P<0.05.
3.4. Treatment with Erythromycin Alters the Numbers of Tregs
in the Lungs of Rats. Flow cytometry analysis revealed that
the frequency and the number of Tregs in the lung paren-
chyma of smoking rats were signiﬁcantly lower than that of
theNandCgroups ofcontrolrats(P<0.01,Figure 4),while
the frequency and the number of Tregs in the erythromycin-
treated group of rats were higher than that of the S group
of rats (P<0.05). A similar pattern of the relative levels of
Foxp3mRNAtranscriptswasdetectedinthediﬀerentgroups
of rats. Apparently, treatment with erythromycin mitigated
heavy smoking-induced reduction in the numbers of Tregs
in the lungs of rats.
3.5. Treatment with Erythromycin Alters the Levels of IL-35 in
BALF. IL-35 is an inhibitory cytokine and is predominantly
secreted by Tregs. Next, we determined the levels of IL-35 in
BALF from diﬀerent groups of rats. The concentrations of
IL-35 in the BALF from the S group of rats were signiﬁcantly
lower than that in the N and C groups of control rats
(Figure 5). Interestingly, the levels of IL-35 in the BALF from
E group of rats were similar to that in the N and C groups of
rats and were signiﬁcantly higher than that in the S group of
rats. Apparently, treatment with erythromycin increased the
levels of IL-35 responses in the lungs of rats.
4. Discussion
COPD and emphysema are common destructive inﬂamma-
tory diseases that are leading causes of mortality worldwide.
The smoking-induced emphysema is thought to be an auto-
immune disease and is mediated predominantly by Th1 res-
ponses in the lung [15]. In this study, we employed a rat
model of smoking-related airway inﬂammation and emphy-
sema to test the therapeutic eﬀect of treatment with ery-
thromycin and the potential mechanisms. Our data showed
that treatment with erythromycin signiﬁcantly reduced
smoking-induced lung inﬂammation and damages, consis-
tentwithourpreviousﬁndings[28].Furthermore,treatment
with erythromycin increased the numbers of Tregs, accom-
panied by increased levels of inhibitory IL-35 in the lungs of
rats. The increased levels of IL-35 may contribute to the inhi-
bition of erythromycin on smoking-related inﬂammation.
Our novel ﬁndings extend previous observations and suggest
























































































































































Figure 2: Treatment with erythromycin reduces the numbers of inﬂammatory inﬁltrates in the lungs of rats. BALF samples were collected
from individual rats and the cells were stained with May-Gr¨ unwald-Giemsa. The numbers of total inﬂammatory inﬁltrates, macrophages,
lymphocytes,andneutrophilswereanalyzed,accordingtotheirmorphologicalcharacters.Dataareexpressedasmeannumbersofindividual
samples and mean values (lines) for each group (n = 10). Group N: rats exposed to regular air without any special treatment; Group C: rats
exposed to regular air and were treated with erythromycin; Group S: rats exposed to smoking air and were treated with saline; Group E: rats
exposed to smoking air and were treated with erythromycin daily for nine weeks beginning at the forth weeks smoking. ∗P<0.05.
airway inﬂammation by upregulating Treg responses in pa-
tients with COPD in the clinic.
Macrolideantibiotics havebeen usedforthetreatmentof
lung inﬂammation in patients with COPD in the clinic [31].
Previous studies have shown that macrolides, especially for
erythromycin, can modulate immune responses and inhibit
inﬂammationinpatientswithDBandCF[32].Indeed,long-
termtreatmentwithalowdoseofmacrolidebeneﬁtspatients
with COPD by its anti-inﬂammatory activities. In this study,
we employed a well-known cigarette-smoking-inuced rat
emphysemamodelandexaminedtheeﬀectoftreatmentwith
erythromycin on the airway inﬂammation and lung dam-
ages. We detected high values of MLI, great numbers of
inﬂammatory inﬁltrates, and high levels of TNF-α and IL-8
in the lungs of smoking rats, demonstrating that heavy
smoking-inucedemphysemaandairwayinﬂammationinthe
lungs of rats. Furthermore, we found that treatment with
erythromycin mitigated the smoking-induced emphysema
and reduced the numbers of inﬂammatory inﬁltrates and
levels of TNF-α and IL-8 in the lungs of rats. Our data were
consistent with a previous report that treatment with clar-
ithromycin for six months decreases airspace enlargement in
the smoke-induced emphysema in mice [33]. Our ﬁndings
supportthenotionthaterythromycininhibitsairwayinﬂam-
mation [28].
Heavy smoking can modulate the function of antigen-
presenting cells, which may induce T-cell autoimmunity
against the lungs and Th1 immunity has been thought to be
related to the pathogenic process of COPD [15, 34]. Micro-
bials, such as erythromycin, can modulate T-cell responses
and inhibit airway inﬂammation [23, 27, 35]. Notably, Tregs
are potent regulators of T-cell autoimmunity and inﬂam-
mation and IL-35 is predominantly produced by Tregs and































































Figure 3: Treatment with erythromycin decreases the levels of TNF-α, IL-8 in the lungs of rats. The levels of TNF-α and IL-8 in BALF of
individual rats were analyzed by ELISA. Data shown are mean values of individual samples from three separate experiments and mean values
for each group of rats (n = 10). Group N: rats exposed to regular air without any special treatment; Group C: rats exposed to regular air and
were treated with erythromycin; Group S: rats exposed to smoking air and were treated with saline; and Group E: rats exposed to smoking
air and were treated with erythromycin daily for nine weeks beginning at the forth weeks smoking. ∗P<0.05, ∗∗P<0.01.
that treatment with erythromycin enhanced Treg responses,
which may contribute to the inhibition of airway inﬂamma-
tion. Evidentially, in comparison with that in the smoking
rats, treatment with erythromycin signiﬁcantly increased the
frequency and the numbers of Treg inﬁltrates in the lungs.
Furthermore, treatment with erythromycin upregulated the
levels of Foxp3 mRNA transcripts in the lungs. In addition,
treatment with erythromycin increased the levels of IL-35
in the BALF, given that Tregs can inhibit pathogenic T-cell
responses and IL-35 is crucial for the function of Tregs [10].
Although the increased Treg responses in the lungs by treat-
ment with erythromycin were moderate the signiﬁcantly
reduced inﬂammation suggests that marginal eﬀect of ery-
thromycin on increasing Treg response in the lung may be
suﬃcient in suppressing smoking-related inﬂammation. We
understand that our data did not demonstrate that the in-
creased Treg responses were responsible for the inhibition of
smoke-related lung inﬂammation. We are interested in fur-
ther investigation of whether adoptive transfer of Tregs or
inactivation of Tregscouldmodulate smoke-induced inﬂam-
mationandexaminingwhetherneutralizationofIL-35could
change the eﬀect of treatment with erythromycin on smoke-
induced lung damage in rats.
While there is clear evidence that treatment with macro-
lide antibiotics inhibits eﬀector T-cell proliferation and cyto-
kine production there currently is little information on
how macrolide antibiotics modulate T-cell immunity. Ery-
thromycin may modulate the components of gut microbiota
and promote the development of Tregs. Indeed, the compo-
nents of gut microbiota are crucial for the development of
Tregs in rodents. Furthermore, a previous study has shown
that Roxithromycin inhibits chemokine-induced chemotaxis
of Th1 and Th2 cells but does not aﬀect regulatory T-cell
migration [36]. Erythromycin may act, like Roxithromycin,
and inhibit the migration of eﬀector T cells, but not Tregs,
leading to relative increase in the numbers of Tregs in the
lungs of rats. In addition, erythromycin has been shown
to downregulate dendritic cell function and cytokine pro-
duction, particularly for LPS-stimulated dendritic cell mat-
uration and activation [37]. However, treatment with ery-
thromycin does not aﬀect peptidoglycan-induced dendritic
cell activation [37]. It is possible that erythromycin may
modulate dendritic cell function toward to promoting Treg
development. Indeed, we found that treatment with ery-
thromycin upregulated Foxp3 transcription and IL-35 pro-
duction. Given that IL-35 has been shown to promote Treg
proliferation the increased levels of IL-35 may feedback en-
hance Treg responses in the lungs of rats. We are interested in
further investigating the mechanisms underlying the role of
erythromycin in regulating Treg responses.
5. Conclusions
In summary, treatment of COPD currently remains a sig-
niﬁcant challenge, and pharmacological understanding of
drugs for the treatment of COPD is crucial for the control
of disease progression. Our data indicated that treatment
with erythromycin signiﬁcantly reduced smoking-related
lunginﬂammationanddamagesandmodulatedTregandIL-
35 responses in the lungs of rats. Therefore, our ﬁndings may
provide new insights into understanding the pharmacologi-
cal action of erythromycin in the management of COPD in








































































































































































































Figure 4: Treatment with erythromycin modulates the frequency and the number of Treg and Foxp3 transcription in the lungs of rats. The
frequency of Tregs, the number of Tregs (b), and the relative levels of Foxp3 mRNA transcripts to β-actin in the lungs (c) were analyzed by
ﬂow cytometry (a) and RT-PCR, respectively. The isolated lung cells were stained with anti-CD4 and anti-Foxp3 and subjected to ﬂow cyto-
metry analysis. Data are expressed as mean numbers of individual samples and mean values (lines) of each group or the mean ± SD of the
relative levels of Foxp3 mRNA transcripts of each group (n = 10 per group) of rats from three separate experiments. Group N: rats exposed
to regular air without any special treatment; Group C: rats exposed to regular air and were treated with erythromycin; Group S: rats exposed
to smoking air and were treated with saline; and Group E: rats exposed to smoking air and were treated with erythromycin daily for nine































Figure 5: Treatment with erythromycin increases thelevels of IL-35
in the lungs of rats. The levels of IL-35 in BALF of individual rats
were analyzed by ELISA. Data shown are mean values of individual
samples from three separate experiments and mean values (lines)
of each group of rats (n = 10). Group N: rats exposed to regular
air without any special treatment; Group C: rats exposed to regular
air and were treated with erythromycin; Group S: rats exposed to
smokingairandweretreatedwithsaline;andGroupE:ratsexposed
to smoking air and were treated with erythromycin daily for nine
weeksbeginningattheforthweekssmoking. ∗P<0.05, ∗∗P<0.01.
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